News | Robotic Systems | May 13, 2016

New Study Reveals Safety and Feasibility of Robotically Assisted Percutaneous Coronary Intervention in Complex Cases

corpath, corindus, cath lab robot, CORA-PCI

May 13, 2016 — A first-of-its kind study using robotic technology to remotely control coronary guidewires and stents reported on the feasibility of performing percutaneous coronary intervention (PCI) on patients with complex coronary lesions. Similar clinical outcomes compared to the PCI procedure performed manually were reported. Results of the 18-month complex robotically assisted percutaneous coronary intervention (CORA-PCI) trial were presented as a late-breaking clinical trial at the Society for Cardiovascular Angiography and Interventions (SCAI) 2016 Scientific Sessions. 

The technology of performing robotically assisted PCI is relatively new and was recently approved by the FDA. Previous studies were performed largely on patients with simple coronary lesions. “For the first time, we’ve shown nearly identical outcomes with a group of very complex patients,” said Ehtisham Mahmud, M.D., FACC, FSCAI, the study’s lead author and division chief, cardiovascular medicine and director, interventional cardiology and cardiac cath lab at the University of California, San Diego School of Medicine. He noted that approximately 80 percent of lesions treated in the CORA-PCI trial were complex, which is more reflective of contemporary interventional cardiology practice.

Consecutive robotic and manual procedures were performed by a single operator and a total of 334 PCI procedures were analyzed (108 robotic, 157 lesions; 226 manual, 336 lesions) in 315 patients (age 67.7 ± 11.8). The majority of patients (78 percent) were male. Clinical success was similar between the groups (99.1 percent for robotic PCI vs. 99.6 percent for manual PCI, p=0.64).

In the robotically assisted PCI group, over 90 percent of the procedures were performed entirely robotically or with minimal manual assistance. Procedure time was longer (robotic PCI 44:30 ± 26:04 min vs. manual PCI 36:34 ± 23:03 min, p=0.005) and remained significant after accounting for Syntax score, primary lesion length, and complexity (p=0.026); however, the longer procedure time was limited to the low complexity lesions. Propensity matched analysis (n=94 each group) confirmed the longer procedure time in the R-PCI group with comparable clinical success (98.9 percent vs. 100 percent, p=1). No increase in resource utilization or patient radiation exposure was reported with robotic PCI.

Furthermore, Mahmud said the data presented show that using robotic technology to perform PCI is a viable alternative to manual PCI with the potential benefits of reducing radiation exposure and orthopedic injuries to the interventional cardiologist.

Mahmud reports the following disclosures: Corindus, consulting and clinical trial support. No support received for this study.

For more information: www. 

Related Content

Videos | Cath Lab | March 15, 2018
A discussion with Hitinder Gurm, M.D., MBBS, FACC, professor, internal medicine, and associate chief clinical officer
News | Cath Lab | February 27, 2018
The American College of Cardiology (ACC) and the Saudi Arabian Cardiac Interventional Society have partnered to...
News | Cath Lab | February 23, 2018
February 23, 2018 — CorFlow Therapeutics AG announced that the company will present new insights into the coronary mi
Teleflex Launches Next-Generation Sympro Elite and Expro Elite Snares
Technology | Cath Lab | February 07, 2018
Teleflex Inc. has announced 510(k) clearance by the U.S. Food and Drug Administration (FDA) and U.S. commercial launch...
SCAI Advocacy Committee Highlights Reimbursement Reform Efforts in 2017
News | Cath Lab | January 30, 2018
The Society for Cardiovascular Angiography and Interventions (SCAI) highlighted the efforts of its Advocacy Committee...
IAC Releases Cardiovascular Catheterization Accreditation Program
News | Cath Lab | January 25, 2018
January 25, 2018 – The Intersocietal Accreditation Commission (IAC) announced the release of its Cardiovascular Cathe
Videos | Cath Lab | January 04, 2018
Bernadette Speiser, BSN, MSN, CCRN, RCIS, a cardiac cath/EP nurse at Palo Alto Veterans Hospital, Palo Alto, Calif.,
FDA Initiates Class I Recall of Sterilmed Reprocessed Agilis Steerable Introducer Sheath
News | Cath Lab | January 04, 2018
The U.S. Food and Drug Administration (FDA) announced a Class I recall of Sterilmed’s Agilis Steerable Introducer...
The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA atherectomy system. Athar Ansari, M.D.

The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA system. 

Feature | Cath Lab | November 24, 2017 | Athar Ansari, M.D., FACC
As debates about the current state and future of healthcare rage in Congress, the media and healthcare settings acros
Overlay Init